{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:07:19Z","timestamp":1774922839084,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"internal funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Increasing application of vancomycin due to the high prevalence of MRSA infections has led to the emergence of vancomycin intermediate-resistant Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). Consequently, the need for alternative therapies that target MRSA has become evident.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the synergy between (lipo)glycopeptides (LGP\/GPs) (vancomycin, teicoplanin, telavancin, dalbavancin and oritavancin) and \u03b2-lactams (ceftaroline, cefepime, cefazolin and oxacillin) against MRSA, hVISA, VISA and daptomycin non-susceptible (DNS) phenotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty randomly selected clinical MRSA strains (i.e. 5 MRSA, 5 hVISA, 5 VISA and 5 DNS) were assessed versus LGP\/GPs alone and LGP\/GPs in combination with \u03b2-lactams for MICs. Although verification of antibiotic potency against bacterial strains is assessed by the microbroth dilution (MBD) MIC method recommended by the CLSI, some antibiotics need modified assay conditions in order to demonstrate their optimal activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Addition of \u03b2-lactams reduced MIC values of LGP\/GPs against all strains (up to 160-fold reduction). In general, LGPs (dalbavancin, oritavancin and telavancin) were more active (significant differences in MIC values, up to 8-fold) compared with vancomycin and teicoplanin. The majority of these combinations were bactericidal and superior to any single agent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This report has examined the susceptibility patterns of LGP\/GPs and their combination with \u03b2-lactams. Of interest, the impact of susceptibility tests (in terms of MIC plates and their surface area) on the synergistic activity in 24\u2009h time\u2013kill experiments was apparent for LGPs. Further clinical research is required to investigate synergy with LGP\/GPs and \u03b2-lactams against these Staphylococcus strains.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa237","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T19:10:16Z","timestamp":1590520216000},"page":"2894-2901","source":"Crossref","is-referenced-by-count":14,"title":["Combinations of (lipo)glycopeptides with \u03b2-lactams against MRSA: susceptibility insights"],"prefix":"10.1093","volume":"75","author":[{"given":"Razieh","family":"Kebriaei","sequence":"first","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth A","family":"Rice","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivedita B","family":"Singh","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle C","family":"Stamper","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Rybak","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"},{"name":"School of Medicine, Wayne State University, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"2020101416050765800_dkaa237-B1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, biochemistry and mechanism of action of glycopeptide antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020101416050765800_dkaa237-B2","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond vancomycin: the tail of the lipoglycopeptides","volume":"37","author":"Klinker","year":"2015","journal-title":"Clin Ther"},{"key":"2020101416050765800_dkaa237-B3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42 Suppl 1","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020101416050765800_dkaa237-B4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1345\/aph.1G417","article-title":"Telavancin: a novel lipoglycopeptide antibiotic","volume":"43","author":"Charneski","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2020101416050765800_dkaa237-B5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0976-500X.81918","article-title":"Telavancin: a novel lipoglycopeptide antibiotic","volume":"2","author":"Damodaran","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"key":"2020101416050765800_dkaa237-B6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"2020101416050765800_dkaa237-B7","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"key":"2020101416050765800_dkaa237-B8","first-page":"CD007022","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2020101416050765800_dkaa237-B9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0195-6701(86)90011-3","article-title":"Structure and mechanism of action of teicoplanin","volume":"7 Suppl A","author":"Parenti","year":"1986","journal-title":"J Hosp Infect"},{"key":"2020101416050765800_dkaa237-B10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: a novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2020101416050765800_dkaa237-B11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jinf.2004.05.006","article-title":"Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo","volume":"50","author":"Darouiche","year":"2005","journal-title":"J Infect"},{"key":"2020101416050765800_dkaa237-B12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"2020101416050765800_dkaa237-B13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","article-title":"Pharmacokinetic\u2013pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia","volume":"50","author":"Bhavnani","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B14","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/JB.179.8.2557-2566.1997","article-title":"Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus","volume":"179","author":"Sieradzki","year":"1997","journal-title":"J Bacteriol"},{"key":"2020101416050765800_dkaa237-B15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","article-title":"Combinations of vancomycin and \u03b2-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin","volume":"43","author":"Climo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2020101416050765800_dkaa237-B17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020101416050765800_dkaa237-B19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"2020101416050765800_dkaa237-B21","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B22","year":"2020"},{"key":"2020101416050765800_dkaa237-B23"},{"key":"2020101416050765800_dkaa237-B24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2020101416050765800_dkaa237-B25"},{"key":"2020101416050765800_dkaa237-B26","doi-asserted-by":"crossref","first-page":"e01743","DOI":"10.1128\/AAC.01743-18","article-title":"Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic\/pharmacokinetic model","volume":"63","author":"Kebriaei","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B27","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1128\/AAC.02624-14","article-title":"High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery","volume":"58","author":"Nesseler","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B28","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/BF02618296","article-title":"Surface treatments and cell attachment","volume":"20","author":"Ramsey","year":"1984","journal-title":"In Vitro"},{"key":"2020101416050765800_dkaa237-B29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/AAC.01428-12","article-title":"Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic\/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection","volume":"57","author":"Belley","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B30","doi-asserted-by":"crossref","first-page":"e01760","DOI":"10.1128\/AAC.01760-18","article-title":"Effects of microplate type and broth additives on microdilution MIC susceptibility assays","volume":"63","author":"Kavanagh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2020101416050765800_dkaa237-B32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/14656566.2014.876991","article-title":"New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections","volume":"15","author":"Burke","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2020101416050765800_dkaa237-B33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2020101416050765800_dkaa237-B34","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1128\/AAC.00361-08","article-title":"Assessment by time\u2013kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"52","author":"Belley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B35","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/AAC.00169-16","article-title":"Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state","volume":"60","author":"Belley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050765800_dkaa237-B36","first-page":"82","article-title":"Evaluation of dalbavancin alone and in combination with \u03b2-lactam antibiotics against resistant phenotypes of Staphylococcus aureus","volume":"74","author":"Xhemali","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020101416050765800_dkaa237-B37","first-page":"1","article-title":"Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA","volume":"7","author":"Lai","year":"2017","journal-title":"Sci Rep"},{"key":"2020101416050765800_dkaa237-B38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.11150\/kansenshogakuzasshi1970.80.243","article-title":"Combined effect of vancomycin or teicoplanin plus a \u03b2-lactam antibiotic in mouse infection models caused by \u03b2-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)","volume":"80","author":"Hatano","year":"2006","journal-title":"Kansenshogaku Zasshi"},{"key":"2020101416050765800_dkaa237-B39"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2894\/33885402\/dkaa237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2894\/33885402\/dkaa237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:45:28Z","timestamp":1666658728000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/10\/2894\/5863533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa237","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,6,26]]}}}